Breast Cancer Medtech Company Appoints Joe Kiani as Chairman

Clairity: Pioneering Breast Cancer Risk Assessment with High-Caliber Leadership

Boston-based medtech innovator Clairity has made headlines with the recent appointment of industry veteran Joe Kiani as chairman of its board of directors. This strategic move comes at a critical juncture for the company, which has made significant strides in the breast cancer screening landscape. Clairity has developed an advanced AI-powered risk assessment platform designed specifically for analyzing standard screening mammograms to predict a woman’s five-year risk of developing breast cancer. This technology received FDA De Novo authorization last year, marking a significant milestone in its commitment to enhancing patient outcomes through early intervention.

Kiani’s extensive background in the medical device sector positions Clairity for further success. He is the founder of Irvine-based Masimo Corp., a company recognized for revolutionizing patient monitoring and which went public in 2007, amassing a market cap exceeding $7 billion. With this impressive track record, Kiani’s leadership is expected to guide Clairity in navigating the complex healthcare landscape while leveraging innovative technology for breast cancer prevention. “Clairity is at a defining moment,” Kiani stated, emphasizing the unique opportunity the company has to lead the next era in breast cancer screening and intervention.

The technology behind Clairity’s platform is not just revolutionary; it’s timely. Early detection significantly influences breast cancer survival rates, and Clairity’s AI-driven solutions aim to empower healthcare providers with critical insights derived from standard mammogram screenings. By accurately estimating a woman’s risk, physicians can make more informed decisions and tailor screening protocols, potentially leading to more effective preventative care and improved patient outcomes. The demand for such advanced solutions is growing within health systems, aligning perfectly with Clairity’s objectives.

Moreover, Clairity’s leadership transitions don’t stop at Kiani. The company has also appointed its founder, Connie Lehman, as Chief Executive Officer. Lehman’s deep expertise and commitment to breast cancer research further bolster Clairity’s mission. With her at the helm, the company is poised not just for expansion, but for revolutionizing the methodologies currently employed within breast cancer screening processes. This dual leadership of Kiani and Lehman combines innovation with practical medical insights, setting a compelling foundation for developing proprietary healthcare technologies.

Funding plays a pivotal role in the successful commercialization of Clairity’s platform. The company raised a notable $43 million in a Series B financing round in 2025, aimed specifically at supporting the commercialization and wider clinical adoption of its technology. This investment highlights the confidence stakeholders have in Clairity’s potential to make a lasting impact in the medtech sector. Furthermore, as healthcare continues to evolve, robust funding allows Clairity to accelerate its mission, ensuring that advancements in breast cancer diagnostics reach the women who need them most.

In conclusion, Clairity is set to navigate an exciting phase in the medtech industry with the appointment of Joe Kiani and Connie Lehman into key leadership roles. Their combined expertise and Clairity’s groundbreaking AI technology position the company ideally for future growth. With a focus on early detection and risk assessment in breast cancer, Clairity is not only pioneering the future of screening but is also committed to enhancing patient care and outcomes. As the healthcare sector increasingly turns to innovative solutions, Clairity stands at the forefront, ready to transform breast cancer screening into a proactive and preventive process.